Correlation Between CRISPR Therapeutics and Charles Schwab

Can any of the company-specific risk be diversified away by investing in both CRISPR Therapeutics and Charles Schwab at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CRISPR Therapeutics and Charles Schwab into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CRISPR Therapeutics AG and The Charles Schwab, you can compare the effects of market volatilities on CRISPR Therapeutics and Charles Schwab and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CRISPR Therapeutics with a short position of Charles Schwab. Check out your portfolio center. Please also check ongoing floating volatility patterns of CRISPR Therapeutics and Charles Schwab.

Diversification Opportunities for CRISPR Therapeutics and Charles Schwab

0.4

Correlation Coefficient

CRISPR Therapeutics  Charles Schwab

Very weak diversification

The 3 months correlation between CRISPR and Charles is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and The Charles Schwab in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Charles Schwab and CRISPR Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CRISPR Therapeutics AG are associated (or correlated) with Charles Schwab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Charles Schwab has no effect on the direction of CRISPR Therapeutics i.e., CRISPR Therapeutics and Charles Schwab go up and down completely randomly.

Pair Corralation between CRISPR Therapeutics and Charles Schwab

Assuming the 90 days trading horizon CRISPR Therapeutics AG is expected to under-perform the Charles Schwab. In addition to that, CRISPR Therapeutics is 1.83 times more volatile than The Charles Schwab. It trades about -0.04 of its total potential returns per unit of risk. The Charles Schwab is currently generating about 0.13 per unit of volatility. If you would invest  5,098  in The Charles Schwab on October 23, 2024 and sell it today you would earn a total of  704.00  from holding The Charles Schwab or generate 13.81% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.31%
Values	Daily Returns

CRISPR Therapeutics AG  vs.  The Charles Schwab

CRISPR Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Charles Schwab

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in The Charles Schwab are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak technical indicators, Charles Schwab sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with CRISPR Therapeutics and Charles Schwab

The main advantage of trading using opposite CRISPR Therapeutics and Charles Schwab positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CRISPR Therapeutics position performs unexpectedly, Charles Schwab can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Charles Schwab will offset losses from the drop in Charles Schwab's long position.

The idea behind CRISPR Therapeutics AG and The Charles Schwab pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.